Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 3 for:    Open Studies | "Chondrocalcinosis"
Previous Study | Return to List | Next Study

Role of ASICs in Human Inflammatory Pain

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Centre Hospitalier Universitaire de Nice
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice Identifier:
First received: May 15, 2013
Last updated: October 20, 2016
Last verified: October 2016
In recent years, ion channels have emerged as new therapeutic targets for pain. Among these channels, ASICs (Acid Sensing Ion Channels) are of particular interest because they are directly activated by extracellular acidity, which is a major cause of pain. Indeed, many painful conditions such as ischemia, inflammation, tumor development or tissue incision are accompanied by tissue acidification. ASIC are excitatory ion channels that are expressed in neurons, including nociceptive sensory neurons. In humans, the use of amiloride, a nonspecific inhibitor of ASICs, has demonstrated their role in the perception of pain induced by subcutaneous injections of acidic solutions. ASICs thus appear as new candidates capable of mediating pain in humans. A growing number of data suggests that, in addition to protons, ASICs may also be activated by one or more endogenous compounds produced during inflammation. The purpose of this research project is to identify these compounds by testing the effects of human inflammatory exudates on ASICs activity. The discovery of such compounds would definitely validate ASICs as novel therapeutic targets for pain treatment in humans

Gouty Arthritis
Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Study of the Role of Acid Sensing Ion Channels (ASICs) in Human Inflammatory Pain

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • activation or miodulation to Electrical potential of ionic channel in the synovial fluid [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    only once because it's an single ponction of sinovial fluid.

Estimated Enrollment: 20
Study Start Date: November 2012
Estimated Study Completion Date: December 2018
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
(osteoarthritis, chondrocalcinosis, gouty arthritis, rheumatoid arthritis)

Inclusion Criteria:

  • septic arthritis
  • gonarthrosis in push-inflammatory
  • microcrystalline arthropathies
  • chronic inflammatory rheumatism

Exclusion Criteria:

  • refusal to participate in the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01867840

Contact: Véronique BREUIL, Pr 0492035512

Service de Rhumatologie Recruiting
Nice, France, 06000
Contact: Véronique BREUIL, Pr    0492035512   
Sub-Investigator: Emmanuel DEVAL, PhD         
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Principal Investigator: Véronique BREUIL, Pr service de rhumatologie
  More Information

Responsible Party: Centre Hospitalier Universitaire de Nice Identifier: NCT01867840     History of Changes
Other Study ID Numbers: 12-PP-07 
Study First Received: May 15, 2013
Last Updated: October 20, 2016
Health Authority: France: The Commission nationale de l’informatique et des libertés

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Arthritis, Gouty
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases processed this record on October 21, 2016